Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) CTO Jay S. Stout sold 2,740 shares of the firm’s stock in a transaction on Wednesday, October 23rd. The stock was sold at an average price of $29.53, for a total value of $80,912.20. Following the completion of the sale, the chief technology officer now directly owns 142,186 shares of the company’s stock, valued at approximately $4,198,752.58. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Immunovant Stock Down 0.9 %
NASDAQ IMVT opened at $30.22 on Friday. The company has a 50 day moving average price of $30.07 and a two-hundred day moving average price of $28.94. Immunovant, Inc. has a 12-month low of $24.67 and a 12-month high of $45.58. The stock has a market capitalization of $4.42 billion, a PE ratio of -15.66 and a beta of 0.66.
Immunovant (NASDAQ:IMVT – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.07). During the same period in the previous year, the company posted ($0.57) EPS. As a group, equities analysts anticipate that Immunovant, Inc. will post -2.41 EPS for the current year.
Institutional Trading of Immunovant
Wall Street Analyst Weigh In
IMVT has been the subject of several research analyst reports. JPMorgan Chase & Co. reduced their price objective on Immunovant from $51.00 to $46.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. UBS Group dropped their target price on Immunovant from $42.00 to $41.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $51.00 price target on shares of Immunovant in a report on Monday, September 30th. Raymond James reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Immunovant in a research report on Thursday, October 10th. Finally, Oppenheimer increased their target price on shares of Immunovant from $47.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 9th. Eleven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $48.10.
Read Our Latest Stock Report on Immunovant
About Immunovant
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Featured Stories
- Five stocks we like better than Immunovant
- Financial Services Stocks Investing
- Texas Roadhouse Stock Steering for New Highs This Year
- 5 Top Rated Dividend Stocks to Consider
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Business Services Stocks Investing
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.